midodrine has been researched along with Kidney Failure in 1 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with midodrine and albumin was associated with a slight but significant decrease in plasma renin activity and aldosterone compared to placebo (renin -4." | 2.87 | Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. ( Ariza, X; Castellote, J; Colmenero, J; Córdoba, J; de Prada, G; Fabrellas, N; Garcia-Martínez, R; Ginès, P; Graupera, I; Guevara, M; Huelin, P; Lopez Benaiges, E; Manríquez, M; Márquez, F; Martín-Llahí, M; Moreira, R; Navasa, M; Nazar, A; Pavesi, M; Pose, E; Simón-Talero, M; Solà, E; Solé, C; Suñé, P; Torrens, M; Vargas, V; Ventura, M; Xiol, X, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solà, E | 1 |
| Solé, C | 1 |
| Simón-Talero, M | 1 |
| Martín-Llahí, M | 1 |
| Castellote, J | 1 |
| Garcia-Martínez, R | 1 |
| Moreira, R | 1 |
| Torrens, M | 1 |
| Márquez, F | 1 |
| Fabrellas, N | 1 |
| de Prada, G | 1 |
| Huelin, P | 1 |
| Lopez Benaiges, E | 1 |
| Ventura, M | 1 |
| Manríquez, M | 1 |
| Nazar, A | 1 |
| Ariza, X | 1 |
| Suñé, P | 1 |
| Graupera, I | 1 |
| Pose, E | 1 |
| Colmenero, J | 1 |
| Pavesi, M | 1 |
| Guevara, M | 1 |
| Navasa, M | 1 |
| Xiol, X | 1 |
| Córdoba, J | 1 |
| Vargas, V | 1 |
| Ginès, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation[NCT00839358] | Phase 4 | 199 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for midodrine and Kidney Failure
| Article | Year |
|---|---|
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
Topics: Adult; Aged; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Follow-Up Studies; Humans; | 2018 |